SIGNIFICANCE OF THE SLOWING DOWN OF THE RATE OF DECREASE OF TUMOR MARKERS IN CHILDREN WITH GERMINOGENIC TUMORS

ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH

https://doi.org/10.37469/0507-3758-2018-64-3-378-383

Published 01.03.2018

Svetlana Kuleva⁺⁻
N. Faseeva⁺⁻

Svetlana Kuleva

N.N. Petrov National Medical Research Center of Oncology

N. Faseeva

N.N. Petrov National Medical Research Center of Oncology

##article.numberofdownloads## 25

##article.numberofviews## 103

PDF (Русский)

Keywords

CHILDREN
ALPHA-FETOPROTEIN
HALF-ELIMINATION PERIOD
PREDICTED TIME OF TUMOR MARKER NORMALIZATION
GERMOGENIC TUMOR

How to Cite

Kuleva, S., & Faseeva, N. (2018). SIGNIFICANCE OF THE SLOWING DOWN OF THE RATE OF DECREASE OF TUMOR MARKERS IN CHILDREN WITH GERMINOGENIC TUMORS. Voprosy Onkologii, 64(3), 378–383. https://doi.org/10.37469/0507-3758-2018-64-3-378-383

Abstract

The main tumor markers of germogenic tumors are alpha-fetoprotein (AFP) and ß-subunit of human chorionic gonadotropin. The speed of normalization of tumor markers in each patient is different and its slowing is often prognostically unfavorable factor for the outcome of the disease. Determination of the dynamics of the rate of decrease of AFP is the most important prognostic criterion for patients with secreting germicogenic tumors. The delayed elimination of AFP after the first weeks of polychemotherapy could be the basis for a transition to a more intensive curative program.

https://doi.org/10.37469/0507-3758-2018-64-3-378-383

##article.numberofdownloads## 25

##article.numberofviews## 103

PDF (Русский)

References

Bubley G.J., Carducci M., Dahut W. et al. Eligibility and response guideline for phase II clinical trials in androgenindependent prostate cancer: Recommendations from the prostate-specific antigen working group // J. Clin. Oncol. - 1999. - Vol. 17. - P. 3461-3467.

De Wit R., Collette L., Sylvester R. et al. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance // Br. J. Cancer. - 1998. - Vol. 78. - P. 1350-1355.

Einhorn L.H. Treatment of testicular cancer: A new and improved model // J. Clin. Oncol. - 1990. - Vol. 8. - P 1777 - 1781.

Fizazi K., Culine S., Kramar A. et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors // J. Clin. Oncol. - 2004. - Vol. 22(19). - P. 3868-3876.

Kaatsch P, Hafner C., Calaminus G. et al. Pediatric germ cell tumors from 1987 to 2011: incidence rates, time trends, and survival // Pediatrics. - 2015. - Vol. 135. - P 136-143.

Mardiak J., Salek T., Sycova-Mila Z. et al. Gemcitabine plus Cisplatine and Paclitaxel (GCP) in Second-line Treatment of Germ Cell Tumors (GCT): a phase II Study // Neoplasma. - 2005. - Vol. 52. - P. 243-247.

Mardiak J., Salek T., Sycova-Mila Z. et al. Paclitaxel, Bleomycin, Etoposide, and Cisplatin (T-BEP) as initial treatment in patients (pts) with poor-prognosis germ cell tumors (GCT): A phase II study // Neoplasma. - 2007. - Vol. 54. - P 240-245.

Mazumdar M., Bajorin D.F., Bacik J. et al. Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy // J. Clin. Oncol. - 2001. - Vol. 19. - P 2534-2541.

Rustin G.J., Nelstrop A.E., McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 // J. Clin. Oncol. - 1996. - Vol. 14. - P. 1545-1551.

Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine // Clin. Chemistry. - 1993. - Vol. 39. - P. 561-577.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Svetlana Kuleva, Svetlana Ivanova, Andrey Karitskiy, Darya Zvyagintseva, SINGLE-FACTOR LINEAR REGRESSION MODEL OF HODGKIN’S LYMPHOMA IN ADOLESCENTS , Voprosy onkologii : Vol. 63 No. 2 (2017)
Sergey Alekseev, Yevgeniya Kharchenko, Svetlana Kuleva, Tatyana Semiglazova, MODERN THERAPY FOR RELAPSES AND RESISTANT FORMS OF HODGKIN''S LYMPHOMA , Voprosy onkologii : Vol. 64 No. 3 (2018)
Sergey Alekseev, A. Subora, P. Shilo, I. Ishmatova, Tatyana Semiglazova, Larisa Filatova, Svetlana Kuleva, Yuliya Oleynik, Yuliya Chudinovskikh, Yevgeniya Kharchenko, Margarita Motalkina, Ilya Zyuzgin, S. Shalaev, ANALYSIS OF UNFAVORABLE PROGNOSTIC FACTORS IN PATIENTS WHO RECEIVED HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL HEMOPOIETIC STEM CELLS TRANSPLANTATION FOR RELAPSES AND RESISTANT FORMS OF HODGKIN''S LYMPHOMA , Voprosy onkologii : Vol. 64 No. 3 (2018)
Aleksandr Druy, Svetlana Kuleva, NEUROBLASTOMA IMMUNOTHERAPY , Voprosy onkologii : Vol. 65 No. 2 (2019)
Svetlana Kuleva, Aleksandr Druy, IMMUNOLOGY AND PROSPECTS OF IMMUNOTHERAPY OF THE PRIMARY MALIGNANT BRAIN TUMORS: CELLULAR THERAPY, VIROTHERAPY , Voprosy onkologii : Vol. 66 No. 3 (2020)